Global brokerage firm UBS has initiated coverage on several pharma stocks, highlighting potential upsides and challenges within the sector. The report points to weakening trends in both India and the US, with underappreciated growth slowdowns in these markets. UBS has provided a mixed outlook, issuing both ‘Buy’ and ‘Sell’ ratings on a range of pharmaceutical stocks.Here is a list of 6 pharma stocks on which UBS initiated coverage:
Nasdaq rises 1%, Dow, S&P close higher as weak jobs data tempers rate hike bets
U.S. stocks finished higher following a weaker-than-expected jobs report which eased rate hike expectations. Nonfarm payrolls rose by only 29,000, significantly below economists’ forecasts of
October 2, 2026